Clinical Trial Update: Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating the safety and activity of the oral HIV entry inhibitor AMD11070 in HIV-infected patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• AMD11070

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED